The U.S. Food and Drug Administration (FDA) has approved the use of Spark Therapeutics’ gene therapy Luxturna (voretigene neparvovec-rzyl) for the treatment of a rare
The U.S. Food and Drug Administration (FDA) published its recommendation for a new approach to drug development for rare pediatric diseases. The new approach supports
From 30th March 2019, when the United Kingdom’s (U.K.) is expected to withdraw from the European Union (EU), all EU law will no longer apply
Amsterdam has been selected as the new post-Brexit home for the European Medicines Agency (EMA). It was chosen in a draw of lots between it
The European Medicines Agency (EMA) and the European Network for Health Technology Assessment (EUnetHTA) have finalised “a joint work plan outlining key areas of collaboration
Partners4Access (P4A), the specialists in orphan drug access, are launching a weekly newsletter focussing on key developments in the rare diseases and orphan drugs market
Sophie Schmitz, Managing Partner of Partners4Access, the specialists in orphan drug access, is presenting at the 8th annual meeting of the World Orphan Drug Congress
Partners4Access (P4A) the specialists in orphan drug access, are presenting 3 posters at the International Society for Pharmacoeconomics and Outcomes Research’s (ISPOR) 20th European Congress
Partners4Access (P4A), the specialists in orphan drug access, are launching a new webinar series, in line with their expanding activities in gene therapy. Launching in
